Its summer time and that means you got to put your CROX! CROX has been mauled the past few days mostly due to profit taking and a fearing that insider selling equates to a top. Coupled with a very negative article about CROX in Barron's this week regarding how the insiders had "No Comment" when asked about their massive selling, this was just the piece of information that the shorts need to attack this stock. On the answer section Jim Cramer responded to a question regarding the insider selling of CROX by saying "I would be nervous if they didnt sell. That would show recklessness given the run....The earnings are fine .." WEEKLY CATALYST: Investors will come back to a staple footwear stock which is firing on all cylinders, especially since it is the summer. Insider selling is usually very difficulty to "game" as insiders sell for all different reasons (most of the time the sales are planned well in advance), thus these "concern" will take pressure off the stock to investors who are waiting in on the sidelines. Maybe CROX's management will come out and try to clarify the "No Comment" statement, but that seems unlikely. If your looking to get into CROX now is a great time

Genentech has basically missed out on the recent bull market (as has a good part of bio-tech) and has acted very "doggy" giving investors little to hope for, but it seems as though this trend is over. The problems with Avastin seem to have died down on Wednesday Genentech did what all investors LOVE to see; they highlighted its development pipeline. WEEKLY CATALYST: Investors are now coming back into DNA as its cancer therapies face steeper competition on the market from companies like GlaxoSmithKline Plc. and Amgen Inc. Genentech's breast cancer drug Herceptin is in direct competition with GlaxoSmithKline's Tykerb. Avastin, also a Genentech drug, competes breast cancer market and also in the lung cancer markets with Amgen and Imclone drugs. Bristol-Myers Squibb is also testing its drug Sprycel as a possible breast cancer treatment. "Competition is an important business risk that we take seriously, said Diane Schrick, , speaking at Jefferies Healthcare conference in New York. Genentech's drugs are still showing growth. Avastin sales rose 34 percent to $533 million in the first quarter while in the quarter, a 34 percent increase over the same period last year. Herceptin sales rose 7 percent to $311 million

Dendreon has recently see a HUGE amount of call buying in the July $7.50s and the July $10 options. On Wednesday over 120,000 thousand contracts where traded and over 100,000 of them where call-buys for both in and out of the money July calls. You don't buy that amount of calls on a $7.40 stock because you think it's a good investment; its because investors think something is going to happen and happen soon. DNDN is a super popular and violate stock that has been known to move as much as 40-50% in one trading day. WEEKLY CATALSYT: Large call options buying for this month coupled with a huge short position could move this stock as investors are betting on a positive piece of news to come out any day. Short position of 50% would exacerbate any move to the upside.

Trump Entertainment hit a 52-week low as reported buyout talks hit a snag. Trump's biggest issue is a gap between the purchase price it's looking for and what it's likely to fetch, according to The Philadelphia Inquirer. Trump is in talks with a group led by Dennis Gomes and real estate developer Morris Bailey. The Gomes-led group has offered more than $11 per share, but shareholder Morgan Stanley is seeking more than $17 a share, but rumor has it that Trump wants $22 a share. After TRMP slid 15% in a single day Bear Stearns upgraded the stock citing "Valuations". Weekly Catalyst: While, the odds of a deal happening next week are almost zero, investors will come back into this stock as any leak could move this stock. Remember, there is also a value to Trump in both his name and assets. Stock is at $12.97 yet the book value is at $13 ; that wont last long.

In a 13D filing this morning on 1-800-Flowers.com Inc. RLR Capital Partners disclosed a 5.1% stake (1,307,000 shares) and a letter expressing their current support for the company's management and the initiatives management has undertaken. Weekly Catalyst: Management is now able to set forth businesss plans which have the backing of RLR Capital Parnters.

RTK is the perfect speculative name if oil stays above $70 a barrel. It provides energy independence technologies utilizing domestic resources to produce ultra-clean synthetic fuels in the United States. The company principally licenses a patented and proprietary Fischer-Tropsch coal-to-liquids and gas-to-liquids process to manufacture synthetic diesel fuels and other fuel products. Weekly Catalyst: People might hedge with such alternative names such as RTK as oil continues to rise. Last time oil was above $70 a barrel RTK was trading in the mid $4

NIKE earnings/numbers where it amazes me that an analyst could downgrade FootLocker. Just in case that analyst didn't know Foot Locker primarily sells Nike footwear and clothing gear, those goods that have super-high profit margins and caused Nike to crush numbers. Weekly Catalyst: Senseless downgrade tampered with a rally in this name last week, investors need to look no further then Nike to see how strong the sports retail sector is. Footlocker is ready to rally

T is a great stock, if not just for this week but in general. It has a 3.6% Dividend and has the sole licensing contract for the I-Phone. With the release of the I-Phone and the mass media attention it is getting T is a great beneficiary. Some figurers shows that T is going to get 2-5Million additional subscribers just off of the I-Phone, if these figurers are true that could add $3-4 per share alone on T. Weekly Catalyst: Safest way to play the I-Phone without going long AAPL